PSYENCE BIOMEDICAL LTD.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Psyence Biomedical
Pharmaceutical Preparations, SIC 2834
Psyence Biomedical Ltd. is a clinical-stage biotechnology company that focuses on the research and development of psychedelic therapies. The company develops drug candidates featuring psychedelic compounds, primarily psilocybin-based therapeutics and related chemical analogs. Its product pipeline is currently in preclinical and clinical stages, with indications focused on mental health conditions such as serious mental illnesses. Psyence operates within the biopharmaceutical sector, licensing intellectual property and advancing clinical trials in collaboration with research partners. Once approved, its therapeutic candidates target patients in need of psychiatric treatments, along with healthcare providers and prescribing physicians.
The company maintains its corporate headquarters in Toronto, Ontario, Canada. Its clinical operations and regulatory activities span multiple countries, including an authorized Phase IIb clinical study in Australia and prior regulatory approval in the United Kingdom. Psyence also prepares regulatory submissions for the United States Food and Drug Administration. The organization collaborates with international clinical research organizations and third-party contract manufacturers to conduct its development programs across foreign jurisdictions.
Summary of the business section of Psyence Biomedical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PSYENCE BIOMEDICAL LTD.
- Headquarters
- Toronto, Ontario, Canada
- Address
- 121 Richmond Street West Penthouse, Suite 1300
- Phone
- 27744604171
- Employees
- 12, Mar 31, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A6
- Fiscal year ends
- March 31
- Auditor
- MNP LLP, Toronto, Canada
Stock & identifiers
- Ticker
- PBM
- Other tickers
- PBMWW
- Exchange
- Nasdaq
- IPO date
- Dec 10, 2021
- Shares outstanding
- 2M, Mar 31, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-6.25 reverse, Jun 22, 2026; 1-for-8 reverse, Jun 25, 2025; 1-for-8 reverse, May 5, 2025; 1-for-75 reverse, Jan 23, 2025; 1-for-75 reverse, Nov 26, 2024
- SEC CIK
- 1985062
- CUSIP
- 74449F407
- ISIN
- US74449F4072
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Psyence Biomedical's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As at March 31, 2026, we had 12 employees”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 25, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 1, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |